Global Prescription Drugs Market, By Type (Branded, Generic), Therapy Area (Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynaecology, Endocrinology, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2031.
Prescription Drugs Market Analysis and Size
In the realm of the prescription drugs market, the treatment of medical conditions stands as a primary application. These drugs are instrumental in managing and alleviating symptoms associated with a wide array of health conditions, ranging from common ailments such as headaches and allergies to chronic diseases such as diabetes, hypertension, and cancer. Through targeted pharmaceutical interventions, prescription drugs help patients regain health, manage chronic conditions, and improve their overall well-being. They often serve as essential components of comprehensive treatment plans, working synergistically with other therapeutic modalities such as surgery, physical therapy, and lifestyle modifications.
Global prescription drugs market size was valued at USD 1,128.70 billion in 2023 and is projected to reach USD 2,249.00 billion by 2031, with a CAGR of 9.00% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024-2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Branded, Generic), Therapy Area (Oncology, Immunology, Ophthalmology, Respiratory, Dermatology, Gastroenterology, Urology, Gynaecology, Endocrinology, Others), Route of Administration (Oral, Topical, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E, South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. 'Reddy's Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India)
|
|
Market Opportunities
|
|
Market Definition
Prescription drugs are medications that can be obtained with a written prescription from a licensed healthcare provider such as a doctor or a nurse practitioner. These drugs are typically regulated due to their potential risks and require professional medical guidance for safe and effective use.
Prescription Drugs Market Dynamics
Drivers
- Rising Prevalence of Chronic Diseases Increases the Demand for Prescription Medications
With conditions such as cardiovascular diseases, diabetes, respiratory disorders, and cancer becoming increasingly common, there is a growing need for pharmaceutical interventions to manage symptoms and improve patient outcomes. As these conditions often require long-term medication regimens, the demand for prescription drugs remains consistently high. Pharmaceutical companies focus their research and development efforts on creating innovative drugs to address the specific needs of patients with chronic diseases, driving market growth.
- Growing Aging Population Fuels the Demand for Prescription Medications for Management
As individuals age, they are more prone to developing age-related health conditions, necessitating the use of prescription medications for management and treatment. With a larger proportion of the population entering older age brackets globally, there is a corresponding increase in the demand for prescription drugs to address the healthcare needs of this demographic. Pharmaceutical companies respond to this demand by developing specialized medications tailored to the needs of older adults, driving market growth.
Opportunities
- Expansion of Prescription Medications due to the Advancements in Pharmaceutical Research
Advancements in pharmaceutical research lead to the creation of novel therapies with enhanced efficacy, safety, and tolerability profiles, addressing unmet medical needs and expanding treatment options for various diseases. Cutting-edge technologies such as genomics, proteomics, and high-throughput screening enable more precise drug targeting and personalized medicine approaches, increasing therapeutic effectiveness and patient outcomes. The relentless pursuit of scientific innovation in pharmaceutical research fuels the expansion and evolution of the prescription drugs market.
For instance, The FDA approval of Zolgensma signifies a major stride in pharmaceutical research, offering hope to spinal muscular atrophy (SMA) patients. This gene therapy replaces the faulty gene, potentially stopping disease progression and enhancing quality of life, showcasing the transformative power of gene therapy in medicine.
- Increasing Expenditure on Healthcare Enhances Access to Healthcare Services
As healthcare budgets expand, there is a greater capacity for individuals and healthcare systems to afford prescription medications. This increased spending allows for greater investment in research and development by pharmaceutical companies, leading to the development of innovative drugs. Moreover, it enhances access to healthcare services, including prescription drugs, for a larger segment of the population. This trend fosters growth in the market as more patients can afford and access necessary medications, thereby driving demand and market expansion.
Restraints/Challenges
- Complex Regulatory Requirements for Smaller Pharmaceutical Companies
Stringent regulatory requirements encompass rigorous testing, documentation, and approval processes mandated by regulatory agencies, such as the FDA in the United States and the EMA in Europe. Compliance with these regulations adds substantial time and costs to drug development, hindering the speed at which new medications can reach the market. Moreover, the complexity of regulatory frameworks may deter smaller pharmaceutical companies from pursuing innovative drug development due to the resources required for compliance. This constraint limits market entry, stifles innovation, and can result in delays in bringing new, potentially life-saving drugs to patients in need..
- Growing Generic Competitors Limits the Growth of Prescribed Medications
The entry of generic competitors into the prescribed drugs market impacts the market dynamics. Generic alternatives often offer similar efficacy at lower costs, intensifying competition and eroding the market share of branded drugs. This increased competition can lead to price wars, squeezing profit margins for pharmaceutical companies. As a result, pharmaceutical companies face pressure to innovate and differentiate their products to maintain their competitive edge amidst the influx of generic alternatives.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2020, Lupin Limited launched Mycophenolic Acid Delayed-Release Tablets USP in 180 mg and 360 mg variants. These tablets are designated for adult kidney transplant recipients and pediatric patients (aged 5 and above) who have undergone dialysis for at least six months, aiding in the prevention of organ rejection
- In March 2020, Dr. Reddy’s Laboratories Ltd. launched the generic version of Geodon (Ziprasidone Mesylate) injection in the U.S., catering to schizophrenia patients. This move offers a more cost-effective alternative for patients seeking treatment for their condition
Prescription Drugs Market Scope
The market is segmented on the basis of type, therapy area, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Branded
- Generic
Therapy Area
- Oncology
- Immunology
- Ophthalmology
- Respiratory
- Dermatology
- Gastroenterology
- Urology
- Gynaecology
- Endocrinology
- Others
Route of Administration
- Oral
- Topical
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Prescription Drugs Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, type, therapy area, route of administration, end-users and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.
North America dominates the market due to the region boasts robust healthcare initiatives, driving accessibility and demand for prescription medications. Major pharmaceutical players have established a significant presence, contributing to the market's growth and innovation. Additionally, the region witnesses a surge in disease prevalence, necessitating greater pharmaceutical intervention.
The Asia-Pacific is expected for notable expansion, propelled by various factors. Government initiatives aimed at raising awareness about healthcare, coupled with a surge in research activities, are contributing to this growth. The region boasts substantial untapped markets, a sizable population base, and an escalating demand for high-quality healthcare services, all of which are driving the healthcare sector's advancement in the Asia-Pacific.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Prescription Drugs Market Analysis
The market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. 'Reddy's Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
SKU-